基于结局的局灶节段性肾小球硬化症蛋白尿缓解定义
该研究分析了5个独立队列中466例原发性FSGS且蛋白尿(UPCR>1 g/g)患者,旨在优化与长期肾脏生存相关的蛋白尿缓解定义。新提出的部分缓解定义(蛋白尿降低40%且<1.5 g/g)在验证队列中与更好的预后相关,且经倾向评分校正后与第4、8个月进展风险降低独立相关。
要点
- 新部分缓解定义:蛋白尿降低40%且<1.5 g/g,与长期肾脏生存改善相关
- 传统部分缓解(<3.5 g/g且降低50%)在推导队列中与肾脏生存无关
- 第8个月达到传统部分缓解亦与更好预后相关,但第4个月无此关联
核心结论
- 达到完全缓解或部分缓解(无论新定义或传统定义)均与FSGS患者更好的长期结局相关。
研究设计与样本
- 多队列回顾性分析,纳入5个独立队列共466例原发性FSGS且蛋白尿(UPCR>1 g/g)患者。
主要发现
- 验证队列中,完全缓解组41例中6例进展至肾衰竭(6.6/100患者年),新部分缓解组71例中13例进展(8.5/100患者年),无缓解组116例中51例进展(20.1/100患者年)。
- 第8个月传统部分缓解组85例中19例进展(10.4/100患者年),与更好预后相关;第4个月传统部分缓解无此关联。
- 倾向评分校正后,新部分缓解与第4个月(HR 0.50;P=0.01)和第8个月(HR 0.30;P=0.002)进展风险降低相关。
关键数值与推荐
- 完全缓解定义为UPCR<0.3 g/g;传统部分缓解定义为UPCR<3.5 g/g且较基线降低50%;新部分缓解定义为蛋白尿降低40%且UPCR<1.5 g/g(基于89例ROC分析,敏感性0.70,特异性0.77)。
临床怎么用
- 在FSGS临床试验和临床评估中,可考虑采用新部分缓解定义(蛋白尿降低40%且<1.5 g/g)作为替代终点。
- 传统部分缓解定义在早期(第4个月)可能不够敏感,建议关注第8个月及以后的蛋白尿变化。
局限性
- 研究为回顾性队列分析,新定义基于小样本ROC分析推导,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Proteinuria is used as an indicator of FSGS disease activity, but its use as a clinical trial end point is not universally accepted. The goal of this study was to refine proteinuria definitions associated with long-term kidney survival. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on 466 patients with primary FSGS with proteinuria (urine protein-to-creatinine ratio >1 g/g) were analyzed from five independent cohorts. Proteinuria by months 1, 4, and 8 after study baseline was categorized by conventional definitions of complete (<0.3 g/g) and partial remission (<3.5 g/g and 50% reduction in proteinuria). Novel remission definitions were explored using receiver operating curves. Kaplan-Meier methods were used to estimate the associations of proteinuria with progression to ESRD or a 50% loss in kidney function. Propensity score-adjusted Cox proportional hazards models were used to adjust for baseline proteinuria, eGFR, and therapy. RESULTS: In the initial derivation cohort, conventional partial remission was not associated with kidney survival. A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77). In the validation cohort analyses, complete remission was associated with better prognosis (6 out of 41 patients progressed to kidney failure; 6.6 per 100 patient-years) as was the novel partial remission (13 out of 71 progressed; 8.5 per 100 patient-years), compared with those with no response (51 out of 116 progressed; 20.1 per 100 patient-years). Conventional partial remission at month 8, but not month 4, was also associated with better response (19 out of 85 patients progressed; risk=10.4 per 100 patient-years). Propensity score-adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002). CONCLUSIONS: Reaching either a complete or partial remission using a novel or conventional definition was associated with better long-term outcomes in patients with FSGS. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_02_20_CJASNPodcast_18_3_T.mp3.
引用
- Troost JP, Trachtman H, Nachman PH, et al. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017. PMID: 29167190. doi:10.2215/CJN.04780517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。